Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Rankning i aktier #27038
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Aktiekurs
$1.48
Senast synkroniserad: 2023-05-31
Marknadsvärde
$35.54M
Förändring (1 dag)
-5.73%
Förändring (1 år)
0.00%
Land
US
Handel TCR2 Therapeutics Inc. (TCRR)

Kategori

Aktiekurshistorik för TCR2 Therapeutics Inc. (TCRR)
Högsta slutkurs: $1.83 den 2023-05-01

Lägsta slutkurs: $16.51 den 2019-02-01
Aktiekurshistorik för TCR2 Therapeutics Inc. från 2019 till 2026
Årlig aktiekursutveckling
År Prestanda
2023 73.43%
2022 -78.52%
2021 -83.60%
2020 79.84%
2019 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$552.07 39.99%
US
$168.77 527.63%
US
$1.03K 56.22%
NL
$120.74 -14.98%
AU
$758.23 6.53%
CH